Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274547 · ClinicalTrials.gov registry record · Phase 3
Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,829
- Enrollment target
NCT00274547 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,829 participants.
The verdict
NCT00274547, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,829 participants
- Enrollment target
Study Summary
The primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD experiencing an exacerbation and the proportion of patients hospitalized for an exacerbation during a six month observation period.
Interventions
- DRUG Tiotropium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,829 participants |
| Start Date | 2001-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274547
The ClinicalTrials.gov registry entry for NCT00274547 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,829 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tiotropium is the first listed.
NCT00274547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274547 about?
NCT00274547 is a clinical study titled "Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)". The primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD experiencing an exacerbation and the proportion of patients hospitalized for an exacerbation during a six month observatio...
What is the current status of trial NCT00274547?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,829 participants. The study started on 2001-09.
What interventions are being tested in trial NCT00274547?
The interventions under investigation include: Tiotropium (DRUG).
Who is sponsoring clinical trial NCT00274547?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.